Key Points

Research suggests US tariffs, up to 25% since April 2025, increase costs for German diagnostic exports, potentially reducing market share in the US.
It seems likely that companies like Siemens Healthineers and Carl Zeiss face higher expenses, with Siemens managing impacts via global strategies and Carl Zeiss seeing up to 2% margin shrink.
The evidence leans toward trade disruptions, with Germany exporting $3.37 billion in medical instruments to the US in 2022, now facing higher costs and supply chain challenges.
There is controversy over long-term effects, with some seeing domestic production boosts, while others fear job losses and economic strain in Germany.

Background

The US has implemented tariff policies under President Donald Trump, aiming to protect domestic industries by imposing duties up to 25% on various imports, including medical diagnostic equipment from Germany, effective from April 2025. These measures target countries with significant trade deficits, impacting Germany’s export-driven diagnostic sector, which relies heavily on the US market.

Impact on German Companies

Major German firms like Siemens Healthineers and Carl Zeiss are affected. Siemens, with a global manufacturing strategy, expects minor impacts, while Carl Zeiss Meditec may see gross margins shrink by up to 2 percentage points due to 23% of its business relying on US imports. Roche Diagnostics‘ specific impacts are less clear, but the industry faces increased costs and potential market share losses.

Economic and Trade Implications

In 2022, Germany exported $17.6 billion in medical instruments, with $3.37 billion to the US, a key market. Tariffs could reduce exports, lead to job losses (up to 300,000 warned by research), and disrupt supply chains, especially for components from Asia or the US, potentially affecting innovation and investment.

Survey Note: Detailed Analysis of US Tariff Impacts on Germany’s Diagnostic Industry

Introduction and Context

The US tariff policy, particularly under President Donald Trump’s administration since January 2025, has introduced significant challenges for global trade, with a focus on protecting American industries through high import duties. The „America First Trade Policy,“ launched on Trump’s first day, and the „Fair and Reciprocal Plan“ from February 13, 2025, target countries with large trade deficits, including Germany, with tariffs up to 25% on medical devices effective from April 2025 (PwC’s US Tariff Industry Analysis). This policy aims to reduce the US trade deficit, which reached over $1 trillion in goods in 2023, but it poses risks to Germany’s export-oriented diagnostic industry, known for high-precision analysis equipment like those from Siemens Healthineers, Roche Diagnostics, and Carl Zeiss.

Germany’s diagnostic sector is a cornerstone of its economy, with companies producing advanced medical technologies for global markets, especially the US, where demand is driven by rising healthcare expenditures. The tariffs, part of a broader strategy including investigations into unfair trade practices expected to conclude by April 1, 2025, could disrupt this trade, raising costs and potentially leading to retaliatory measures from the EU, as noted in recent analyses (KPMG in Germany).

US Tariff Policies and Specific Rates

The US employs the Harmonized Tariff Schedule (HTS), based on the Harmonized System (HS) codes, to classify imports. Medical diagnostic equipment often falls under HS code 9018, covering instruments for physical or chemical analysis. While specific tariff rates for German diagnostic equipment are not uniformly detailed in public data, reports indicate potential rates of 20–25% for medical devices, aligning with broader tariff hikes on EU nations (Medical Device Network). For instance, the PwC analysis suggests tariff measures could escalate from $0.5 billion to $63 billion annually for the pharmaceutical, life science, and medical device sector, with pharmaceutical tariffs potentially adding $76 billion in revenue, though exact figures for diagnostics remain elusive (PwC’s US Tariff Industry Analysis).

Impact on German Diagnostic Companies

The impact varies by company. Siemens Healthineers, a leader in imaging and diagnostic systems, has stated in recent earnings calls that US tariffs on imports from Mexico, Canada, and China will have a „minor impact,“ with strategies like twin factory setups mitigating effects (Siemens Healthineers confident it can cope with Trump tariffs | MedTech Dive). Their Q1 2025 revenue was €5.48 billion, up 5.9%, suggesting resilience, but they anticipate headwinds remain manageable (Siemens Healthineers shares rise on Q1 revenue beat despite China order delays | Reuters).

Carl Zeiss Meditec, focusing on ophthalmology and microsurgery, faces more direct pressure, with reports suggesting gross margins could shrink by up to 2 percentage points, given 23% of its business depends on US sales through imports (US Tariffs Challenge Carl Zeiss Meditec And Smith & Nephew – Finimize). This aligns with their significant US presence, with over 50% of employees based there, potentially exacerbating cost pressures (Annual Report Carl Zeiss Meditec AG).

Roche Diagnostics, another key player, has less public data on tariff impacts, but industry-wide analyses suggest similar cost increases, potentially affecting pricing and competitiveness in the US market, where diagnostic testing is crucial for healthcare decisions (Roche | Roche Diagnostics).

Trade Data and Economic Consequences

Trade data from 2022 shows Germany exported $17.6 billion in medical instruments, with the US as the largest destination at $3.37 billion, highlighting its importance (Medical Instruments in Germany | The Observatory of Economic Complexity). Imports from the US were $2.4 billion, indicating a robust transatlantic trade. However, with tariffs, these exports face increased costs, potentially reducing volumes. Research from the Institute for Macroeconomic and Conjunctural Research warns of up to 300,000 job losses in Germany due to escalated tariffs, with the diagnostic sector, reliant on exports, particularly vulnerable, especially smaller suppliers lacking resources for market diversification (KPMG in Germany).

Supply chain disruptions are another concern, as diagnostic equipment often relies on components from Asia or the US, and extended tariffs could delay production and innovation, impacting R&D investments. The economic strain could also lead to reduced consumer confidence and investment, with Germany’s stagnant economy facing additional challenges from these tariffs (Trump’s Tariffs Pose a New Threat for Germany’s Stagnant Economy – The New York Times).

Strategic Responses and Mitigation Strategies

To counter these impacts, German companies are exploring several strategies. Diversifying markets, such as focusing on Asia or the Middle East, where demand for diagnostic technology is growing, is one approach, requiring investments in local distribution networks (KPMG in Germany). Siemens Healthineers, for instance, is leveraging its global supply network, including US-based units, to mitigate effects, while considering local production to bypass tariffs (Inside Siemens Healthineers‘ US Supply Chain Investment | Supply Chain Magazine).

Innovation is another avenue, with companies investing in AI-driven diagnostics or personalized medical technologies to differentiate products, reducing price sensitivity (Medical Device Network). Political negotiations at the EU level, such as potential deals involving US natural gas or defense purchases, could also secure exemptions for medical devices, though outcomes remain uncertain (PwC’s US Tariff Industry Analysis).

Conclusion and Future Outlook

The US tariff policy presents significant challenges for Germany’s diagnostic industry, with increased costs, potential market share losses, and supply chain disruptions. While short-term impacts are clear, long-term strategies like market diversification and innovation could enhance resilience. The controversy lies in balancing domestic production benefits against economic strains, with international cooperation and fair trade practices crucial for resolving these tensions. As of April 6, 2025, the dynamic nature of tariff policies underscores the need for adaptive strategies to navigate this uncertain landscape.

Table: Key Trade Data for German Medical Instruments (2022)

Category	Value (USD Billion)	Notes
Total Exports	17.6	Includes diagnostic equipment
Exports to US	3.37	Largest single market
Total Imports	11.4	Includes US at $2.4 billion
Potential Tariff Impact	Up to 25% on exports	Increases costs significantly

Economic Effects of US Tariffs on Germany’s Diagnostics